Equities

Abera Bioscience AB

Abera Bioscience AB

Actions
  • Price (SEK)4.18
  • Today's Change0.01 / 0.24%
  • Shares traded175.00
  • 1 Year change+1.95%
  • Beta1.1548
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3.301512
Total Receivables, Net0.770.770.30
Total Inventory------
Prepaid expenses3.381.490.19
Other current assets, total0017
Total current assets7.441829
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net1.891.891.89
Long term investments0.03----
Note receivable - long term------
Other long term assets------
Total assets9.352031
LIABILITIES
Accounts payable2.201.670.99
Accrued expenses1.230.971.17
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.270.160.07
Total current liabilities3.692.802.22
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total--00
Total liabilities3.692.802.22
SHAREHOLDERS EQUITY
Common stock1.161.030.93
Additional paid-in capital655952
Retained earnings (accumulated deficit)(61)(44)(25)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.470.470.47
Total equity5.661729
Total liabilities & shareholders' equity9.352031
Total common shares outstanding141312
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.